SUMMARY -Tigecycline susceptibility testing (TST) presents a tremendous challenge for clinical microbiologists. Previous studies have shown that the Epsilometer test (E-test) and Vitek 2 automated system signifi cantly overestimate the minimum inhibitory concentrations for tigecycline resistance compared to the broth microdilution method (BMM). Th is leads to very major errors or false susceptibility (i.e. the isolate is called susceptible when it is actually resistant). Th e aim of this study was to compare E-test against BMM for TST in carbapenem-resistant and carbapenem-susceptible Acinetobacter (A.) baumannii and to analyze changes in tigecycline susceptibility between two time periods (2009-2012 and 2013-2014), with BMM as the gold standard. Using the EUCAST criteria, the rate of resistance to tigecycline for the OXA-23 MBL-positive, OXA-23 MBL-negative and carbapenemase-negative strains for BMM was 54.5% (6/11), 29.4% (5/17) and 2.7% (1/37), respectively; the OXA-24/40 and OXA-58 producing organisms did not exhibit any resistance. With E-test, all OXA-23 MBL-positive organisms (11/11), 23.5% (4/17) of OXA-23 MBL-negative, and 4.1% of OXA-24/40 (3/74) strains displayed tigecycline resistance; there were no resistant strains among the OXA-58 and carbapenemase-negative isolates. Resistance emerged in the bacterial isolates from 2013 to 2014. Although tigecycline does not display cross-resistance, the highest rates of resistant A. baumannii isolates were observed among those producing VIM MBL, regardless of the testing method. Th ese fi ndings suggest that the commercial E-test does not provide reliable results for TST of A. baumannii. Further confi rmation with the dilution method should be recommended, particularly in cases of serious infections.
Introduction
Acquired carbapenem resistance is an emerging problem in Acinetobacter (A.) baumannii due to the production of acquired carbapenemases of class A (KPC) 1 , class B metallo--lactamases (MBLs) of the IMP, VIM, SIM and NDM families [2] [3] [4] [5] [6] , and class D carbapenem-hydrolyzing oxacillinases (OXA-23-, OXA-40-, OXA-58-, OXA-143-and OXA-238-like) [CHDL] 7-12 . Carbapenem-resistant A. baumannii (CRAB) isolates have been reported worldwide 13 . Carbapenem resistance in A. baumannii is a growing concern in Croatia and neighboring countries [14] [15] [16] [17] [18] [19] [20] . In addition to the hospital setting, CRAB has also been identifi ed in environmental samples in Croatia [21] [22] [23] . CRAB isolates are frequently associated with serious infections such as ventilator-associated pneumonia, septicemia and urinary tract infections, specifi cally in intensive care units [24] [25] . Th ey are often a cause of wound, skin and soft tissue infections, and secondary meningitis 25 . Tigecycline and colistin are often last-resort antibiotics for the treatment of infections associated with carbapenemase-producing organisms. Tigecycline, the fi rst semisynthetic glycocycline, is a minocycline derivative that overcomes major tetracycline resistance mechanisms 26 . However, tigecycline resistance has also emerged 27 . Th erapeutic decisions often rely on appropriate susceptibility testing. Th e issue is that tigecycline susceptibility testing (TST) remains a major challenge for clinical microbiologists. Th us far, there are no clear guidelines established by either the Clinical and Laboratory Standards Institute (CLSI) 28 or the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for TST of A. baumannii.
In most studies, the breakpoints applied for Enterobacteriaecae include the susceptibility breakpoint of ≤1 mg/L and the resistance breakpoint of ≥4 mg/L. Disk-diff usion test is not appropriate for susceptibility testing for tigecycline. Previous studies have shown that the Epsilometer test (E-test) and Vitek 2 system signifi cantly overestimate the minimum inhibitory concentrations (MICs) of tigecycline compared to the broth microdilution method (BMM), leading to very major errors (i.e. false susceptibility) 29, 30 . Th e aim of this study was to compare two diff erent methods for TST (E-test and BMM) in carbapenem-resistant and carbapenem-susceptible A. baumannii and to analyze dynamic changes in tigecycline susceptibility between two collection periods (2009-2012 and 2013-2014) . Th e fi rst period (2009-2012) was chosen because it was in that time-frame that the fi rst carbapenem-resistant isolates were identifi ed in both countries (Republic of Croatia and Republic of Bosnia and Herzegovina). During the second period (2013) (2014) , it was observed that tigecycline resistance had emerged and this prompted further evaluation of its prevalence and TST problems. In this study, BMM was considered as the gold standard for TST.
Material and Methods

Bacteria
During the two collection periods, a total of 154 bacterial isolates were obtained. Within the scope of this multicentre study, the isolates from 2009 to 2012 were retrieved from 13 diff erent hospital centers in Croatia and from the Mostar General Hospital in Bosnia and Herzegovina. Th e isolates from the second period (2013-2014) were collected in two centers in Croatia, the Pula General Hospital and Godan Nursing Home in Zagreb. Bacterial strains were identifi ed by conventional biochemical testing (matrix-assisted laser desorption/ionization time-of-fl ight mass spectrometry, MALDI-TOF MS) and verifi ed by polymerase chain reaction (PCR) for bla OXA-51 gene. Molecular characterization of carbapenem resistance was performed as in previous studies [16] [17] [18] [19] [20] .
Antibiotic susceptibility testing
Th e isolates were classifi ed as multidrug-resistant (MDR), extensively drug-resistant (XDR) or pandrug-resistant (PDR) according to Magiorakos et al. 31 . Susceptibility to tigecycline was determined by BMM and E-test. Antimicrobial susceptibility was confi rmed by BMM in Mueller-Hinton broth in 96-well microtiter plates according to the CLSI guidelines 28 . Pseudomonas aeruginosa ATCC 27853 and A. baumannii ATCC 19606 were used as quality control strains. Since CLSI does not have interpretative criteria for TST for A. baumannii, resistance rates were calculated according to the EUCAST criteria for Enterobacteriaceae 32 or the U. S. Food and Drug Administration (FDA) criteria 33 , with resistance breakpoints of >2 or ≥8 mg/L, respectively.
Interpretation of data
Categorical agreement (CA) was defi ned as the percentage of isolates recorded in the same susceptibility category by BMM and E-test as defi ned previously Acta Clin Croat, Vol. 57, No. 4, 2018 Tigecycline susceptibility testing by Zarkotou et al. 30 . Category discrepancies were grouped as follows: (i) very major errors (VME) in cases where BMM indicated resistance and the comparative method indicated susceptibility; (ii) major errors (ME) when an isolate was categorized as susceptible by BMM and resistant by the comparative method; and (iii) minor errors (mE) when there was one interpretation category diff erence between BMM and the comparative method. Essential agreement (EA) was considered to be the percentage of MICs within 1 doubling dilution of the MIC determined by BMM 30 .
Results
Isolates with acquired oxacillinases were labeled MDR or XDR, as described by Magiorakos et al. 31 . When a MIC breakpoint of >2 mg/L was applied according to the EUCAST criteria for defi ning resistance to tigecycline 32 , the rate of resistance for BMM was 54.5% (6/11) for OXA-23 MBL-positive, 29.4% (5/17) for OXA-23 MBL-negative, and 2.7% (1/37) for carbapenemase-negative strains. Th e OXA-24/40-and OXA-58-producing organisms did not exhibit any resistance. In contrast, in E-test, all OXA-23 MBL-positive organisms (11/11), 23.5% (4/17) of OXA-23 MBL-negative, and 4.1% (3/74) of OXA-24/40 strains showed resistance to tigecycline, as displayed in Table 1 . Th ere were no resistant strains among the OXA-58 and carbapenemase-negative isolates. Using the FDA criteria with a resistance breakpoint of ≥8 mg/L 33 , no resistant isolates were detected, regardless of the testing method. (Table 1) .
When BMM was considered the gold standard for antibiotic susceptibility testing, 5 (45.5%) MBL-positive and 8 (10.7%) OXA-24/40 isolates were noted as resistant instead of susceptible, demonstrating a ME of E-test (Table 2) . VME (i.e. resistant strain being classifi ed as susceptible) was identifi ed in only one (Table 2) . Th e CA was highest in OXA-23 MBL-negative strains (70.6%) and lowest in carbapenemase-negative strains (27.0%).
Discussion
Although tigecycline does not display cross-resistance, the highest rates of resistance were observed among the VIM MBL-producing isolates, regardless of the testing method. Emergence of tigecycline resistance was detected for isolates from the 2013-2014 collection period, whereas those from 2009 to 2012 were fully susceptible. Tigecycline testing by E-test produced higher MICs, yielding ME in 45.5% of MBL-positive isolates, while VME was detected in only one carbapenemase-negative strain. Th e rates of EA of approximately 80% to 90% and CA of 60% to 70% were similar to those found by Zarkotou et al. 30 . Th ere are no published studies so far on the accuracy of particular tests in isolates with diff erent carbapenemresistance mechanisms.
According to the results of this study, E-test did not provide reliable results. Hence, these should be substantiated by the dilution method. Th is is especially important in case of severe infections. Although considered the gold standard, BMM is laborious, timeconsuming and requires educated staff . In addition, these fi ndings confi rm the elevated MICs of tigecycline by E-test compared to BMM, as previously detailed by other authors. However, the discrepancies between these two methods were less pronounced in our study than in the published literature, where the MICs of BMM were overestimated two-to three-fold by the E-test 30 . Like the present study, false-resistant outcomes (i.e. MEs) have also been reported in previous studies 29, 30 . Th e explanation provided by Marchaim et al. is that E-test detects heteroresistance that is very common in A. baumannii and cannot be identifi ed by broth methods 34 . Th e phenomenon of increased MICs by Etest is unique only for A. baumannii and has not been detected in Enterobacteriaceae 34 . Th e resistance to tigecycline was predominantly associated with VIMproducing organisms. Nonetheless, a limitation of this study was that the MBL-positive isolates from the nursing home in Zagreb belonged to a single clone. It is diffi cult to explain the reason for cross-resistance in MBL-positive isolates since MBLs are encoded on mobile genetic elements, whereas tigecycline resistance is due to hyperexpression of effl ux pumps. A possible explanation may be that the carbapenemaseproducing organisms have a greater ability to acquire other resistance traits as well.
Conclusions
Given that BMM is time-consuming and necessitates educated staff , it is not routinely performed in most laboratories. Instead, either the E-test or Vitek 2 is preferred. Clinicians and laboratory personnel alike should be made aware of the discordances between Etest and other microbial sensitivity testing methods, particularly in critically ill patients. Th erefore, according to our results, BMM should be recommended for TST of A. baumannii. 0/37 (0%) 10/37 (27.0%) 32/37 (86.5%) 10/37 (27.0%) VME = very major error; ME = major error; mE = minor error; EA = essential agreement; CA = categorical agreement
